Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study
Titel:
Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study
Auteur:
Sánchez-Rovira, Pedro Antón, Antonio Barnadas, Agustí Velasco, Amalia Lomas, María Rodríguez-Pinilla, María Ramírez, José Luis Ramírez, César Ríos, María José Castellá, Eva García-Andrade, Carmen San Antonio, Belén Carrasco, Eva Palacios, José Luis